Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9
By Heather Cartwright & Keshav Mahawar
Pharma Deals Review: Vol 2015 Issue 6 (Table of Contents)
Published: 19 Jun-2015
DOI: 10.3833/pdr.v2015.i6.2108 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Signalling its intent to stay at the head of the cellular immunotherapy field, Juno Therapeutics has agreed to collaborate with genome editing specialist Editas Medicine to create next-generation chimeric antigen receptor (CAR-T) and high-affinity T cell receptor (TCR) therapies for the treatment of cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS